8,582 Shares in Alkermes plc (NASDAQ:ALKS) Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP bought a new stake in Alkermes plc (NASDAQ:ALKS - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 8,582 shares of the company's stock, valued at approximately $247,000.

Several other large investors have also recently bought and sold shares of ALKS. Renaissance Technologies LLC boosted its position in shares of Alkermes by 1.1% during the 4th quarter. Renaissance Technologies LLC now owns 5,478,728 shares of the company's stock worth $157,568,000 after acquiring an additional 57,697 shares in the last quarter. American Century Companies Inc. raised its stake in Alkermes by 6.5% during the fourth quarter. American Century Companies Inc. now owns 3,450,707 shares of the company's stock worth $99,242,000 after buying an additional 209,740 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Alkermes by 4.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,019,508 shares of the company's stock worth $86,842,000 after buying an additional 128,701 shares during the last quarter. Avoro Capital Advisors LLC bought a new stake in Alkermes in the fourth quarter valued at $70,462,000. Finally, Loomis Sayles & Co. L P increased its stake in Alkermes by 22.3% in the fourth quarter. Loomis Sayles & Co. L P now owns 2,302,905 shares of the company's stock valued at $66,232,000 after purchasing an additional 419,969 shares in the last quarter. 95.21% of the stock is owned by institutional investors.

Alkermes Stock Performance

Shares of ALKS traded up $0.64 during midday trading on Friday, hitting $30.89. The company had a trading volume of 833,234 shares, compared to its average volume of 1,732,716. The company's 50-day simple moving average is $29.86 and its 200-day simple moving average is $30.82. The firm has a market capitalization of $5.09 billion, a P/E ratio of 14.24, a P/E/G ratio of 2.20 and a beta of 0.51. Alkermes plc has a 1 year low of $22.90 and a 1 year high of $36.45.

Alkermes (NASDAQ:ALKS - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $0.13 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.19). The firm had revenue of $306.51 million during the quarter, compared to analysts' expectations of $307.53 million. Alkermes had a net margin of 23.57% and a return on equity of 30.80%. Alkermes's quarterly revenue was down 12.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.43 EPS. Equities analysts predict that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. UBS Group reissued a "sector perform" rating on shares of Alkermes in a research report on Monday, April 28th. Wall Street Zen cut shares of Alkermes from a "strong-buy" rating to a "buy" rating in a research report on Monday, May 5th. HC Wainwright reaffirmed a "neutral" rating on shares of Alkermes in a research report on Friday, May 2nd. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Alkermes from $40.00 to $52.00 and gave the company a "buy" rating in a research report on Thursday, March 27th. Finally, Royal Bank of Canada raised their price objective on shares of Alkermes from $39.00 to $40.00 and gave the company a "sector perform" rating in a research note on Friday, May 2nd. Four research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $38.85.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.